The influence of growth hormone deficiency on bone health and metabolisms.

IF 1.4 Q3 RHEUMATOLOGY Reumatologia Pub Date : 2023-01-01 Epub Date: 2023-08-31 DOI:10.5114/reum/170244
Arnika Wydra, Izabella Czajka-Oraniec, Jakub Wydra, Wojciech Zgliczyński
{"title":"The influence of growth hormone deficiency on bone health and metabolisms.","authors":"Arnika Wydra,&nbsp;Izabella Czajka-Oraniec,&nbsp;Jakub Wydra,&nbsp;Wojciech Zgliczyński","doi":"10.5114/reum/170244","DOIUrl":null,"url":null,"abstract":"<p><p>Growth hormone (GH) is a key peptide hormone in the regulation of bone metabolism, through its systemic and paracrine action mediated directly as well as by insulin-like growth factor-1 (IGF-1). Growth hormone exerts pleiotropic effects leading to an increase in linear bone growth, accumulation of bone mineral content and preservation of peak bone mass. Furthermore, it influences protein, lipid, and carbohydrate metabolism.Growth hormone deficiency (GHD) causes a low bone turnover rate leading to reduced bone mineral density (BMD) and increased bone fragility. The results of GH insufficiency are the most pronounced among children as it negatively affects longitudinal bone growth, causing short stature and in adolescents, in whom it hinders the acquisition of peak bone mass. Most studies show that treatment with recombinant human growth hormone (rhGH) in GHD patients could improve BMD and decrease fracture risk. This review aims to summarize the pathophysiology, clinical picture and management of bone complications observed in GHD.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"61 4","pages":"239-247"},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/62/RU-61-170244.PMC10515129.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/reum/170244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Growth hormone (GH) is a key peptide hormone in the regulation of bone metabolism, through its systemic and paracrine action mediated directly as well as by insulin-like growth factor-1 (IGF-1). Growth hormone exerts pleiotropic effects leading to an increase in linear bone growth, accumulation of bone mineral content and preservation of peak bone mass. Furthermore, it influences protein, lipid, and carbohydrate metabolism.Growth hormone deficiency (GHD) causes a low bone turnover rate leading to reduced bone mineral density (BMD) and increased bone fragility. The results of GH insufficiency are the most pronounced among children as it negatively affects longitudinal bone growth, causing short stature and in adolescents, in whom it hinders the acquisition of peak bone mass. Most studies show that treatment with recombinant human growth hormone (rhGH) in GHD patients could improve BMD and decrease fracture risk. This review aims to summarize the pathophysiology, clinical picture and management of bone complications observed in GHD.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生长激素缺乏对骨骼健康和代谢的影响。
生长激素(GH)是调节骨代谢的关键肽激素,通过其直接介导的全身和旁分泌作用以及胰岛素样生长因子-1(IGF-1)。生长激素具有多效性作用,可增加骨的线性生长、骨矿物质含量的积累和峰值骨量的保持。此外,它还影响蛋白质、脂质和碳水化合物的代谢。生长激素缺乏(GHD)导致骨转换率低,导致骨密度(BMD)降低和骨脆性增加。生长激素不足的结果在儿童中最为明显,因为它对纵向骨生长产生负面影响,导致身材矮小,在青少年中,它阻碍了峰值骨量的获得。大多数研究表明,重组人生长激素(rhGH)治疗GHD患者可以改善骨密度,降低骨折风险。这篇综述旨在总结GHD中观察到的骨并发症的病理生理学、临床表现和处理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Reumatologia
Reumatologia Medicine-Rheumatology
CiteScore
2.70
自引率
0.00%
发文量
44
审稿时长
10 weeks
期刊最新文献
Bilateral rapidly destructive coxopathy in rheumatoid arthritis. Level of glial cell derived neurotrophic factor in the blood plasma of rheumatoid arthritis patients and its relationship with alexithymia. Patterns and prevalence of psychiatric morbidity among individuals with rheumatoid arthritis. Assessment of neurocognitive function in patients with Behçet's disease. Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1